Evidence map›Paper›PMID 35047562›Full record

ArticleFrontiers in molecular biosciences2021

2-Sulfonylpyrimidines as Privileged Warheads for the Development of

Fabian Barthels, Jessica Meyr, Stefan J Hammerschmidt, Tessa Marciniak, Hans-Joachim Räder, Wilma Ziebuhr, Bernd Engels, Tanja Schirmeister

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Beyond Antibiotics: What the Future Holds.Antibiotics (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Substitution-Induced Mechanistic Switching in SMolecules (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Fabian BarthelsInstitute for Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University, Mainz, Germany.
Jessica MeyrInstitute of Physical and Theoretical Chemistry, Julius-Maximilians-University of Würzburg, Würzburg, Germany.
Stefan J HammerschmidtInstitute for Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University, Mainz, Germany.
Tessa MarciniakInstitute for Molecular Infection Biology, Julius-Maximilians-University of Würzburg, Würzburg, Germany.
Hans-Joachim RäderMax Planck Institute for Polymer Research, Mainz, Germany.
Wilma ZiebuhrInstitute for Molecular Infection Biology, Julius-Maximilians-University of Würzburg, Würzburg, Germany.
Bernd EngelsInstitute of Physical and Theoretical Chemistry, Julius-Maximilians-University of Würzburg, Würzburg, Germany.
Tanja SchirmeisterInstitute for Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University, Mainz, Germany.
University of Würzburg · DEJohannes Gutenberg University Mainz · DEMax Planck Institute for Polymer Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-virulencecovalent inhibitiondrug discoveryquantum mechanicssortase

Identifiers

PMID35047562
PMCPMC8763382
OpenAlexW4205135555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.